Risk of Fatigue and Anemia in Patients With Prostate Cancer Treated With Novel Oral Anti-androgens: A Meta-Analysis of Randomized Controlled Trials

Novel oral anti-androgens (NOAAs) represent a new class of drugs that are being approved for prostate cancer. However, fatigue and anemia are among the most common treatment-related symptoms. Hence, we conducted a meta-analysis of randomized controlled trials (RCTs) to investigate the relative risks...

Descripción completa

Detalles Bibliográficos
Autores principales: Babkoor, Abdulrahman a, Aljabri, Yazeed, Alzubaidi, Ahmad, Alhazmi, Rayan, Alsaedi, Zeyad, Alghamdi, Faris, Tamim, Tariq, Aldagani, Ahmad, Seddiqi, Irfan, Tashkandi, Emad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881206/
https://www.ncbi.nlm.nih.gov/pubmed/35233298
http://dx.doi.org/10.7759/cureus.21560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881206/
https://www.ncbi.nlm.nih.gov/pubmed/35233298
http://dx.doi.org/10.7759/cureus.21560

Ejemplares similares